Vaccine News and Research

RSS

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.

LLNL set off to develop vaccines to treat rheumatoid arthritis and lupus

People afflicted with autoimmune diseases may someday receive help through treatments now under development by a Lawrence Livermore National Laboratory (LLNL) licensee and its' collaborations with two major pharmaceutical companies.

19 Feb 2023

Expert releases open-source compilation of the SARS-CoV-2 molecular structure

A biomedical researcher at the Lankenau Institute for Medical Research (LIMR), part of Main Line Health, has created a groundbreaking resource for scientists seeking to develop new and better vaccines in the fight against COVID-19.

19 Feb 2023

Novel analytical platform quantitatively characterizes mRNA vaccines

Researchers from Tokyo Metropolitan University and RIKEN CSRS have developed a new analytical platform based on liquid chromatography, mass spectrometry and software analysis that quantifies the structure of messenger RNA (mRNA) based medicines.

14 Feb 2023

Psychological trauma related to HIV could make it difficult to end the AIDS epidemic

Failing to address the psychological trauma experienced by many older people living with HIV/AIDS will make it difficult, if not impossible, to end the epidemic, according to a Rutgers study.

8 Feb 2023

Newly discovered gene signature accurately predicts the functioning of P53 variants

In a paper published in PNAS, Maureen Murphy, Ph.D., Deputy Director of Wistar's Ellen and Ronald Caplan Cancer Center and Ira Brind Professor and Program Leader in the Molecular & Cellular Oncogenesis Program, and team have identified a gene signature that accurately predicts the functioning of P53 variants, important information to assessing cancer risk and optimizing choices for cancer therapeutics.

7 Feb 2023

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Cerba Research announced today a Memorandum of Understanding with Teddy Clinical Research Laboratory (Wuxi, China), a preeminent central lab provider covering mainland China, to lay the foundation for an in-depth discussion towards the creation of a Joint Venture.

From Cerba Research 3 Feb 2023

Clinically approved fungal vaccine protects against fungal infections

A new vaccine developed by the University of Georgia might be the first clinically approved immunization to safeguard against invasive fungal infections, which are becoming more common as antifungal drug resistance grows.

From University of Georgia 1 Feb 2023

Scientists develop new design principles to improve cancer vaccines

A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology at Northwestern University.

1 Feb 2023

Research supports the safety and efficacy of COVID-19 vaccination in cancer patients receiving immunotherapy

Research findings published in Frontiers in Immunology show that cancer immunotherapy does not interfere with COVID-19 immunity in previously vaccinated patients.

1 Feb 2023

Analysis of pancreatic cancer's microenvironment reveals cause of tumor cell resistance to immunotherapy

A new study that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.

27 Jan 2023

New revelations on the immune system’s defenses against infections

Cells competing for a place in a germinal center confront a tough admissions process. Germinal centers, which form following exposure to a pathogen or vaccine, serve as a kind of immune system training academy, assisting B cells in refining their response to the threat.

18 Jan 2023

New DNA analysis leads to first accurate tuberculosis genome identification

A novel genome assembly tool that has been created by researchers could lead to the creation of fresh antibiotics for the bacterial infections that cause tuberculosis and other diseases.

From Rutgers University 20 Dec 2022

The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein

...

From The Native Antigen Company 8 Dec 2022

Small fluorescent protein helps researchers to capture deeper, more precise biomedical images

Biomedical and genetic engineers at Duke University and the Albert Einstein College of Medicine have designed a small fluorescent protein that emits and absorbs light that penetrates deep into biological tissue.

7 Dec 2022

Insight into the treatment for Crimean Congo Hemorrhagic Fever Virus

The Crimean Congo Hemorrhagic Fever Virus can be prevented by therapeutically relevant human monoclonal antibodies, according to research led by the University of California, Riverside.

30 Nov 2022

AI creates artificial DNA to control cell protein production

Researchers at Chalmers University of Technology in Sweden have developed synthetic DNA that uses artificial intelligence to control the production of proteins in cells.

25 Nov 2022

Chemically attenuated live DNA virus vaccine prevents viral infection

Rutgers researchers have devised a new way to prevent viral infections: a live-attenuated, replication-defective DNA virus vaccine that utilizes the substance centanamycin to create an altered virus for vaccine development.

From Rutgers University 22 Nov 2022

Atypical antibody shows extremely potent zika-resistant activity

A group of researchers led by Weill Cornell Medicine, New York-Presbyterian, and National Institutes of Health (NIH) investigators has discovered an unusual type of antibody that, even at extremely low concentrations, neutralizes the Zika virus and renders the virus infection undetectable in preclinical models.

22 Nov 2022

The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

From The Native Antigen Company 21 Nov 2022

NIH funds research on mRNA vaccines to stop cancer development

The National Cancer Institute at the National Institutes of Health has awarded a multidisciplinary team of Weill Cornell Medicine researchers a five-year $5.7 million grant to support a center dedicated to creating messenger RNA (mRNA) vaccines to prevent the development of cancer in at-risk groups.

15 Nov 2022